Engineering a Dual-Targeting siRNA Therapeutic with AI-Designed Ligands to Treat the Underlying Biology of Sarcopenia

• Introducing a novel protein-conjugated siRNA modality for muscle that enables targeted delivery to skeletal muscle to overcome limitations of current antibody-based inhibitors, while avoiding off-target tissues
• Leveraging dual-targeting to silence redundant nodes in the inhibitory signalling pathway of muscle growth, moving beyond single-target inhibition to achieve functional recovery
• Demonstrating in vivo delivery, potent target knockdown, and significant functional improvement in models of muscle wasting

Speakers:

Uyanga Tsedev

Co-founder & Chief Scientific Officer

Gensaic